Since its establishment in August 2000, Solgent Co., Ltd. has grown as a molecular diagnostics company for the past 20 years,
proclaiming the vision of 'SolGent 2.0', a new start on the 20th anniversary of its founding, and becoming a leading bio in the era of the 4th industrial revolution.
The DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit is a real-time reverse transcriptase (RT)-PCR test intended for the
qualitative detection(Orf1a, N gene) of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal (throat) swabs,
anterior nasal swabs, mid-turbinate nasal swabs, nasal aspirates, nasal washes, bronchoalveolar lavage (BAL) fluid and sputum from
individuals suspected of COVID-19 by their healthcare provider.